Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph not_applicable
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

NCT03393858
unknownnot_applicable

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

NCT05438342

Clinical Trials (2)

Showing 2 of 2 trials
NCT03393858Phase 1

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Terminated
NCT05438342Not Applicable

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
2